Abstract-Voltage-gated K ϩ channels (K V ) and thromboxane A 2 (TXA 2 ) play critical roles in controlling pulmonary arterial tone under physiological and pathological conditions. We hypothesized that TXA 2 might inhibit K V channels, thereby establishing a link between these two major pathogenic pathways in pulmonary hypertension. The TXA 2 analogue U46619 inhibited I K(V) (E max ϭ56.1Ϯ3.9%, EC 50 ϭ0.054Ϯ0.019 mol/L) and depolarized pulmonary artery smooth muscle cells via activation of TP receptors. In isolated pulmonary arteries, U46619 simultaneously increased intracellular Ca 2ϩ concentration and contractile force, and these effects were inhibited by nifedipine or KCl (60 mmol/L). U46619-induced contractions were not altered by the inhibitors of tyrosine kinase genistein or Rho kinase Y-27632 but were prevented by the nonselective protein kinase C (PKC) inhibitors staurosporine and calphostin C. Furthermore, these responses were sensitive to Gö-6983 but insensitive to bisindolylmaleimide I and Gö-6976. Based on the specificity of these drugs, we suggested a role for an atypical PKC in U46619-induced effects. Thus, treatment with a PKC pseudosubstrate inhibitor markedly prevented the vasoconstriction, the inhibition of I K(V) , and the depolarization induced by U46619. Western blots showed a transient translocation of PKC from the cytosolic to the particulate fraction on stimulation with U46619. These results indicate that TXA 2 inhibits I K(V) , leading to depolarization, activation of L-type Ca 2ϩ channels, and vasoconstriction of rat pulmonary arteries. We propose PKC as a link between TP receptor activation and K V channel inhibition.